Shaila Misri, Jasmin Abizadeh, Andrea B. Eng, Gillian Albert, Deirdre Ryan and Elena Swift Pages 17 - 26 ( 10 )
<i>Objectives:</i> This prospective, open-label study investigated the effectiveness of Quetiapine Extended-Release (XR) in the treatment of Bipolar II Depressive Episode and its impact on quality of life in postpartum, non-lactating women. </p> <p> <i>Method:</i> Of the twenty-six women enrolled, fifteen completed the fourteen week study. Quetiapine XR was initiated at 50 mg and titrated up to 300 mg daily. Rating scales: Hamilton and Montgomery-Asberg Depression Rating Scales (HAM-D and MADRS), Quality of Life Enjoyment Satisfaction Questionnaire (QLES- Q), Pittsburgh Sleep Quality Index (PSQI), Clinical Global Impression Severity Scale (CGI-S), Mini- International Neuropsychiatric Interview (MINI). Weight, blood pressure, sexual side effects were recorded. The Wilcoxon signed rank test analyzed changes in scores. Multiple imputation accounted for missing data. </p> <p> <i>Results:</i> By week 12, depression remitted at 137.5 mg of Quetiapine XR while sleep restored at 114.3 mg. By week 14, quality of life was restored and 86.7% of women were asymptomatic. No significant changes occurred in weight or sexual functioning. Side effects were transient. </p> <p> <i>Conclusion:</i> The preliminary findings from this open-label trial of Quetiapine XR appear promising for mitigating depression and anxiety symptoms and restoring quality of life in postpartum, non-lactating women with Bipolar II Depressive Episode. This is currently the only study to prospectively investigate the medication’s efficacy in a postpartum population. Limitations of this study include its small sample size, open-label design, and lack of a control group.
Anxiety, bipolar II disorder, depression, postpartum, quality of life, quetiapine XR, sleep quality.
, , , , , Reproductive Mental Health Program, BC Women’s Hospital, P1-228 – 4500 Oak Street, Vancouver, British Columbia, V6H3N1, Canada.